Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer

Overview of attention for article published in JNCI Cancer Spectrum, June 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (74th percentile)
Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

policy: 2 policy sources
twitter: 1 X user

facebook: 1 Facebook page

Readers on

mendeley: 96 Mendeley

So far, Altmetric has seen 10 policy documents that reference this research output.

WHO Drug Information 2026, vol. 40, 2 [full issue]

Cited by World Health Organization (WHO) on 07 Jul 2026

The World Health Organization (WHO) is the directing and coordinating authority for health within the United Nations system.

sacituzumab govitecan - Clinical and Pharmacoeconomic combined Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 06 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

olaparib - Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 01 Mar 2023

pembrolizumab - Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 06 Jan 2023

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity, including 6 additional policy documents.